Clearside Biomedical (NSDQ:CLSD) said today that it landed a deal with EyeKor Inc. to support its clinical trials. The companies did not disclose any financial details of the agreement.
Clearside is conducting a Phase III trial of suprachoroidally administered CLS-TA, its suspension formulation of triamcinolone acetonide, in patients with macular edema associated with non-infectious uveitis. The company is also evaluating its suprachoroidal CLS-TA, in combination with intravitreally administered Eyelea (aflibercept), in patients with macular edema associated with retinal vein occlusion.
The Alpharetta, Ga.-based company also has a clinical program for diabetic macular edema.
“EyeKor did an outstanding job in our two completed Phase II trials in uveitis and in RVO, and is continuing to support our clinical research programs,” president & CEO Daniel White said in prepared remarks. “The level of service and the prompt and thoughtful nature of their assistance, coupled with the powerful and efficient Excelsior platform, is not just greatly appreciated, but also highly valued. EyeKor has been a great partner for us and we are looking forward to solidifying our collaboration and to further extending our success in ophthalmology clinical and preclinical programs.”
EyeKor provides image and data management solutions for ophthalmic clinical trials, according to Clearside. According to the deal, Clearside will use EyeKor’s Excelsior cloud-based software platform for clinical and preclinical applications.
The software allows Clearside and its contract research organization partners to manage ocular images and other collected data. Scientists, principal investigators, CRO reps, data managers and reading center graders can all access and track data in real time, Clearside reported.
“We are very pleased to support our partner Clearside, a company solely focused on ophthalmic drug development,” EyeKor CEO Christopher Murphy added. “Our strategic collaboration is an important step for EyeKor to validate the great power of our Excelsior application by assisting Clearside in bringing its ophthalmic therapeutics into the marketplace to benefit patients suffering from serious back-of-the-eye diseases. We look forward to continuing our successful relationship with Clearside.”
